Updated November 20, 2023 at 3:16 p.m. ET
Bayer shares fell sharply after the company prematurely stopped a late-stage study of a blood-thinning drug due to lack of effectiveness and was asked to pay $1.56 billion in a lawsuit over its Roundup weedkiller.
Bayer announced Sunday evening that it had halted a phase 3 clinical trial to test its experimental drug, asundexian, for the prevention of stroke and systemic embolism in patients with heart rhythm disorders, atrial fibrillation .
©2023 x x. 87990cbe856818d5eddac44c7b1cdeb8